64Z.F KEYMED BIOSCIENCES -0001

Healthcare Biotechnology Frankfurt Exchange
7.95 EUR
Close of Nov 11, 2026
4.94 9.60
Market cap
EUR 2.34B
P/E
24.8x
P/B
4.49x
ROE
-18.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 64Z.F undervalued?

Graham number
Price7.95
Graham value3.57
Premium122.6%

64Z.F trades 122.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KEYMED BIOSCIENCES -0001 fundamental analysis

No fundamental analysis for KEYMED BIOSCIENCES -0001 yet.

KEYMED BIOSCIENCES -0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KEYMED BIOSCIENCES -0001

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumo…

Full company profile